Business Context and Reporting Period
This Form 8-K is filed by Nuvilex, Inc. (not Pharmacyte Biotech, Inc.) with a report date of May 26, 2011, though the signature date is June 27, 2012. The filing discloses the completion of an acquisition of Austrianova Singapore Pte. Ltd. (ASPL) and the creation of associated financial obligations.
Key Financial Metrics and Obligations
- Acquisition Consideration: 100,000,000 shares of restricted Nuvilex common stock issued for 100% of ASPL shares.
- Capital Obligation: Nuvilex is obligated to fund $2.5 million for future ASPL operations by December 31, 2012.
- Monthly Funding: Current funding of $60,000 per month in operating capital is required until the total $2.5 million is funded.
- Escrow Status: Both Nuvilex and ASPL shares are held in escrow pending the completion of financing obligations.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the acquisition of ASPL and the issuance of 100 million unregistered, restricted common shares. This transaction creates a new direct financial obligation for Nuvilex to provide significant operating capital to the acquired entity.
Outlook, Risks, and Contingencies
- Contingency: If Nuvilex fails to provide the ongoing operating capital or monthly maintenance payments, the company will receive credit for amounts paid in the form of a percentage of ownership in ASPL, rather than full ownership.
- Extension: The funding deadline of December 31, 2012, may be extended by mutual agreement of the parties.
- Regulatory Status: The shares issued were unregistered and restricted under Rule 144 of the Securities Act of 1933.
Investor Verification Checklist
- Verify the current cash position of Nuvilex to assess the ability to fund the $2.5 million obligation.
- Confirm the status of the escrow arrangement and whether financing obligations have been met.
- Review the impact of the 100 million share issuance on existing shareholder dilution.
- Check for any amendments to the Asset Purchase Agreement regarding the December 31, 2012, funding deadline.